Diosgenin in Dioscorea spongiosa Suppresses Glycolysis-Driven Angiogenesis as a ROCK1 Inhibitor
- 19 April 2025
- journal article
- Published by American Chemical Society (ACS) in Journal of Agricultural and Food Chemistry
- Vol. 73 (17) , 10214-10229
Abstract
The rhizome of Dioscorea spongiosa is used in Chinese herbal medicine as Bixie (BX), a drug with antirheumatic effects. To explore the mechanisms underlying its antiangiogenic actions, adjuvant-induced arthritis (AIA) rats were administered with BX extract for 28 days. The therapeutic efficacy was evaluated by serological, histological, and immunohistochemical tests. Metabolites were quantified by kits and UPLC-MS. The BX extract was separated into 30 fractions by silica gel chromatography. The antiangiogenic effects of reagents were assessed based on wound-healing, migration, and tube-formation experiments using human umbilical vein endothelial cells (HUVECs). Protein targets were pulled down by a biotin-conjugated compound. These proteins and constituents in BX-related samples were identified by LC-MS. The target was validated by molecular simulation, immunoprecipitation, thermal shift assays, and enzymatic digestion. BX mitigated the metabolic abnormalities, inflammation, and synovial invasion of AIA rats. Angiogenesis in white adipose tissues and joints was suppressed, shown by the decrease of vessels, angiogenic cytokines, and CD31. The BX extract inhibited glycolysis and angiogenic capabilities of HUVECs. The expression of some genes/proteins related to VEGF and glycolytic signals was reduced. Diosgenin was the only component with high concentrations in the two most effective fractions and a BX-treated rat's serum. It curbed the glycolysis-fueled activation of HUVECs. Diosgenin competed with biotin-diosgenin when bound to ROCK1. It stabilized ROCK1 and inhibited ROCK1 phosphorylation. Its effects on VEGF-treated cells were similar to GSK429286 (a ROCK1 inhibitor) and weakened by arachidonate (a ROCK1 activator). It hardly affected ROCK1-silenced HUVECs. In short, diosgenin inhibits ROCK1 and suppresses angiogenesis via glycolysis downregulation.Keywords
Funding Information
- National Natural Science Foundation of China (82274465)
- Plans for Major Anhui Provincial Science & Technology Projects (202303a07020001)
- Scientific Research Fund of Wannan Medical College (WK2023ZQN11)
- Key Natural Science Research Project of Anhui Educational Committee (2022AH051242, 2024AH051966, KJ2021A0833)
- Excellent Research and Innovation Team of Anhui Provincial Colleges (2023AH010075)
This publication has 29 references indexed in Scilit:
- In vitro screening of natural product-based compounds for leishmanicidal activityJournal of Parasitic Diseases, 2023
- Resveratrol-induced SIRT1 activation inhibits glycolysis-fueled angiogenesis under rheumatoid arthritis conditions independent of HIF-1αInflammation Research, 2023
- Angiogenesis in adipose tissue and obesityAngiogenesis, 2022
- Angiogenesis as a potential treatment strategy for rheumatoid arthritisEuropean Journal of Pharmacology, 2021
- Rheumatoid Arthritis Pathogenesis, Prediction, and Prevention: An Emerging Paradigm ShiftArthritis & Rheumatology, 2020
- Insights into the treatment of rheumatoid arthritis: A paradigm in medicineJournal of Autoimmunity, 2020
- Targeting ROCK signaling in health, malignant and non-malignant diseasesImmunology Letters, 2020
- Can highly cited herbs in ancient Traditional Chinese medicine formulas and modern publications predict therapeutic targets for diabetes mellitus?Journal of Ethnopharmacology, 2018
- Advanced Studies on Rhizoma Dioscoreae CollettiiChinese Journal of Integrative Medicine, 2016
- The in vivo effects of a fraction from Dioscorea spongiosa on glucocorticoid-induced osteoporosisJournal of Ethnopharmacology, 2016